View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
June 1, 2020

Coronavirus company news summary – Moderna starts doses participants in Phase II Covid-19 vaccine trial – Gilead’s remdesivir receives conditional approval in Taiwan

By Allie Nawrat

1 June 2020

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The Ministry of Health of the Russian Federation has granted a temporary registration certificate to Covid-19 treatment, Avifavir, which produced by the Russian Direct Investment Fund (RDIF) and the ChemRar Group. Said to be Russia’s first Covid-19 drug, Avifavir is a generic version of Japanese anti-flu drug, Avigan.

Moderna has started dosing participants in each age cohort of its Phase II clinical trial of its Covid-19 vaccine candidate, mRNA-1273. The trial, which is expected to involve 600 healthy participants, will assess a 50μg and a 100μg dose of the vaccine. The company intends to work with the US National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase III trial.

The Taiwan Food and Drug Administration has provided conditional approval to Gilead Sciences ’ remdesivir to treat Covid-19, after considering preliminary evidence on the drug’s safety and efficacy and its approval in other countries. Gilead has committed to donate 1.5 million doses of remdesivir, which can treat at least 140,000 patients, to help fight the pandemic.

South Korea-based Celltrion Group has reported positive results from the pre-clinical testing of its Covid-19 antibody treatment, which showed a 100-fold decrease in the viral load of SARS-CoV-2. The pre-clinical study was carried out in an animal model in alliance with Chungbuk National University College of Medicine .

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology